Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL120: Intranasal Insulin Detemir in Alzheimer's and MCI
NCT01595646Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2011
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of insulin detemir in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by Wake Forest University Health Sciences. Primary endpoint: Verbal Memory Composite at 16 weeks. Started Nov 2011; status: completed.
02
Drugs
insulin detemir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01595646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01595646.